(The Hill) – The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the sale of these unapproved medications.

According to the FDA, the companies they contacted made “false or misleading claims” about the GLP-1 products they sold on their websites, including implying “sameness with FDA-approved products and obscuring product sourcing.” (Read More)